Plasma treatment for COVID-19
| ISRCTN | ISRCTN41124564 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN41124564 |
| ClinicalTrials.gov (NCT) | Nil known |
| Clinical Trials Information System (CTIS) | Nil known |
| Protocol serial number | RGAO-2020-0839 |
| Sponsor | Philippine Council for Health Research and Development |
| Funder | Philippine Council for Health Research and Development |
- Submission date
- 28/06/2025
- Registration date
- 16/07/2025
- Last edited
- 14/07/2025
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Infections and Infestations
Plain English summary of protocol
Background and study aims
The study was intended to assess the use of plasma therapy in COVID-19. The study recruited COVID-19-positive patients who were classified as moderate or severe cases. The implementing agency of this study is the University of the Philippines Manila, and the recruitment site is at the Lung Center of the Philippines. The study was recruited starting on December 01, 2020 until November 11, 2024. This study was funded by the Philippine Council for Health Research and Development. For further information, you may reach out to Dr. Jose B. Nevado, Jr
Who can participate?
COVID-19-positive patients who were classified as moderate or severe cases at the Lung Center of the Philippines
What does the study involve?
The participants in the treatment arm received plasma transfusions (up to 8 units, as tolerated, for 7 days; 2 units every other day, with each unit administered 8 to 12 hours apart) in addition to the local standard of care at that time. Participants in the control arm received only what was considered the current local standard of care.
What are the possible benefits and risks of participating?
Benefits in participating in this study includes coverage of standard of care for COVID-19 patients at the Lung Center of the Philippines. Given the study explores plasma transfusion therapy, risks include Transfusion Related Acute Lung Injury (TRALI), Transfusion associated circulatory overload (TACO) infections, allergy, and hemolysis.
Where is the study run from?
The University of the Philippines Manila, Philippines
When is the study starting and how long is it expected to run for?
April 2020 to December 2024
Who is funding the study?
The Philippine Council for Health Research and Development, Philippines
Who is the main contact?
Dr Jose B. Nevado, Jr., jbnevado1@up.edu.ph
Contact information
Scientific, Principal investigator
UP National Institutes Of Health 623, Pedro Gil St, Ermita
Manila
1000
Philippines
 ORCID ID |
0000-0002-5730-7105 |
|---|---|
| jbnevado1@up.edu.ph |
Public, Scientific
Lung Center of The Philippines Quezon Avenue, Barangay Central, Diliman
Quezon City
1100
Philippines
| ssnaval1@up.edu.ph |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomized open-label controlled study design |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Evaluation of plasma therapy for retarding progression and preventing complications in COVID-19 |
| Study objectives | To explore the impact of plasma transfusion therapy in the treatment of COVID-19 and to analyze candidate immune-related proteins that may influence the hyperinflammatory response |
| Ethics approval(s) |
1. Approved 21/08/2020, Lung Center of the Philippines Institutional Ethics Review Board (Lung Center of the Philippines, Quezon Avenue Extension, Quezon City, 1100, Philippines; +63 8924-6101; lcpierb@gmail.com), ref: LCP-CT-021-2020 2. Approved 19/04/2020, UP Manila Research Ethics Board (Pedro Gil St, Ermita, Manila, 1000, Philippines; +63 8554-8400 l; upmreb@post.upm.edu.ph), ref: UPMREB 2020-0644-01 |
| Health condition(s) or problem(s) studied | Treatment of COVID-19 using plasma repletion therapy |
| Intervention | The participants in the treatment arm received plasma transfusions (up to 8 units, as tolerated, for 7 days; 2 units every other day, with each unit administered 8 to 12 hours apart) in addition to the local standard of care at that time. Participants in the control arm received only what was considered the current local standard of care. Computer-generated randomization protocol was used to assign eligible enrolled patients to either the control group (standard of care) or treatment group (plasma transfusion). At the time of randomization, the clinical profile (e.g. with or without co-morbidities) of the individual participant is not known to the investigator in charge of randomization. All enrolled study participants were under the care of an attending licensed pulmonologist (hospital staff). Prior to the study initiation, the attending pulmonologists (hospital staff) who managed Covid patients were oriented thoroughly with this Covid study protocol. A separate study pulmonologist/investigator - was thorioughly trained to assess patients based on inclusion and exclusion criteria, data gathering captured in case report forms, and administration of interventional agent in the proper dose and frequency as well as reporting of outcomes and any adverse events. Once the participant is randomized, the study pulmonologist identifies the patient as a study participant and his randomized group. Study pulmonologist legibly writes the orders in the medical chart that corresponds to participant’s allocation and study protocol. For the treatment group, transfusion of 250 ml appropriately typed and cross-matched plasma was administered every 12 hours for D0, D2, D4, D6 until a total of 8 bags was given. The rest of the management strategies followed the standard of care as defined by the hospital’s clinical pathway algorithm for COVID patient. Management of the participant under the control group followed the hospital’s clinical pathway algorithm of standard of care for Covid patient. A licensed bedside nurse (hospital staff) carried out orders for plasma transfusion. The study pulmonologist visits the participants daily for reporting of outcomes and adverse events. The study pulmonologist has real time access to the medical chart but the attending staff pulmonologist managed the participant. The intervention was done in emergency rooms and wards of the Lung Center of the Philippines. At the time of the study, the Lung Center of the Philippines, a tertiary level hospital, was a designated hospital for Covid patients. |
| Intervention type | Biological/Vaccine |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | 250-mL plasma bag from healthy donors |
| Primary outcome measure(s) |
1. All-cause mortality is measured using vital status from the medical chart at discharge or at 30 days post-enrolment, whichever occurs first |
| Key secondary outcome measure(s) |
Assessed from the medical notes/chart during their course of treatment until discharge: |
| Completion date | 11/12/2024 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Mixed |
| Lower age limit | 18 Years |
| Upper age limit | 75 Years |
| Sex | All |
| Target sample size at registration | 159 |
| Total final enrolment | 121 |
| Key inclusion criteria | 1. Aged 18 to 75 years 2. Presenting with dry cough, fever, dyspnea, or gastrointestinal symptoms on admission 3. Positive RT-qPCR test for SARS-CoV-2 RNA 4. Classified as a moderate or severe case of COVID-19 according to the Philippine College of Physicians (PCP)-Philippine Society for Microbiology and Infectious Diseases (PSMID) COVID-19 Guidelines and the updated COVID-19 treatment algorithm at the time of the study 4.1. Moderate COVID-19 4.1.1. With signs of non-severe pneumonia (e.g., fever, cough, dyspnea, or difficulty breathing), respiratory rate of 21-30/minute, oxygen saturation >92% on room air 4.1.2. with any of the following comorbidities: chronic hypertension, diabetes mellitus, chronic lung disease, obesity, chronic renal disease, persistent asthma 4.1.3. With PaO2/FiO2 (P/F) of >300 4.2. Severe COVID-19 4.2.1. With severe pneumonia or severe acute respiratory infection, defined as follows: fever, cough, dyspnea, respiratory rate >30 breaths/minute, severe respiratory distress 4.2.2. With *P/F of 200-300 4.2.2. oxygen saturation <92%, at FiO2 0.6 |
| Key exclusion criteria | 1. Significant lung pathology as defined by P/F ratio<200, or obvious respiratory distress 2. Significant renal impairment as defined by eGFR<30 3. Malignancy 4. Hemodynamic instability such as refractory hypotension or shock 5. Presence of severe neurological deficits 6. Prior blood/plasma transfusion in the past two months 7. Cannot provide independent informed consent due to mental incapability |
| Date of first enrolment | 01/03/2021 |
| Date of final enrolment | 30/03/2022 |
Locations
Countries of recruitment
- Philippines
Study participating centres
Quezon City
1100
Philippines
Manila
1000
Philippines
Results and Publications
| Individual participant data (IPD) Intention to share | Yes |
|---|---|
| IPD sharing plan summary | Published as a supplement to the results publication |
| IPD sharing plan | The datasets generated and/or analyzed during the current study will be published as a supplement to the results publication |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |
Editorial Notes
30/06/2025: Study's existence confirmed by the Lung Center of the Philippines Institutional Ethics Review Board.
